Pharma Pulse 11/14/24: Global Disparities in Cancer Burden, What Happens if Millions Lose Access to GLP-1s & more

Global Disparities in Cancer Burden

A cross-sectional study uses epidemiological patterns to investigate these disparities, while also predicting the potential shift of these patterns by 2050.

What Will Happen if Millions of Americans Lose Access to GLP-1s at the Same Time?

There has never been such widespread and popularized use of compounded products due to shortages. Will consumers rise up with pitchforks if the party is shut down?

So Human It’s Scary: My Day Alone Talking to Bots That Sound Like Us

Joanna Stern strapped chatbots from Meta, Google, OpenAI and Microsoft to a tripod and took them to the woods to uncover the secrets of AI friendship.

Americans Continue to Struggle to Access Branded GLP-1s as Shortages Continue

Hims & Hers Health, Inc. shared more data on the challenges Americans are facing when trying to access branded GLP-1 medication and introduced a GLP-1 Supply Tracker, where individuals can be a part of advocating for better access to the medications they need.

Gen Li, PhD, MBA on LinkedIn

Precision medicine in clinical development has moved a long way, but the precision in investigator site selection has not. To progress, it is important to be guided by patients we are inspired to treat. At Phesi and in working with our clients, we are leveraging global data from over 130 million patients to improve precision in investigator site selection.
Thanks to Pharmaceutical Executive for covering this increasingly urgent topic.
#PrecisionMedicine #ClinicalDevelopment #ClinicalTrials

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs